Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary
efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively
silences the mRNA encoding for VEGF. The target population are patients with diabetic macular
edema.